Close

More on SGEN

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+41.0% Growth)
- Ratings (4.7 Score)
- Holders
- Event Driven Deals
- FDA Archive

Financials

Income Statement
Balance Sheet
Cash Flow Statement

Upcoming Events

- Earnings (10/27/22)
- M&A (3/31/18 *Est)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Seagen (NQ:SGEN)
Delayed: 136.28 --0 (-0%)
Prev. Close $136.28  
Open$136.28 
52 Wk High$75.36 
52 Wk Low$26.02 
Day High$136.28 
Day Low$136.28 
P/E N/A  
EPS$-0.51 
Volume4 

Friends, Peers and Foes (?): MRK, GMAB, ALPMY, LVTX, SNY (more...)

Oct 6, 2022 08:00 AM Seagen to Host Conference Call and Webcast Discussion of Third Quarter 2022 Financial Results on October 27, 2022
Sep 28, 2022 06:04 AM Jefferies Comments on LAVA Therapeutics (LVTX) and Seagen (SGEN)
Sep 27, 2022 08:03 AM Zai Lab Limited (ZLAB) and Seagen (SGEN) Enter Collaboration and License Agreement for TIVDAK
Sep 27, 2022 08:00 AM Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK® (tisotumab vedotin-tftv)
Sep 27, 2022 08:00 AM Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK® (tisotumab vedotin-tftv)
Sep 27, 2022 08:00 AM Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK® (tisotumab vedotin-tftv)
Sep 26, 2022 05:14 PM UPDATE: Lava Therapeutics NV (LVTX) PT Raised to $28 at SVB Leerink, 'SGEN Licensing Deal Provides Validation to LVTX Platform'
Sep 26, 2022 08:02 AM Seagen (SGEN), LAVA Therapeutics (LVTX) Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors
Sep 26, 2022 08:00 AM Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors
Sep 26, 2022 08:00 AM Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors
View All Articles